Cargando…

Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review

Sodium-Glucose Cotransporter 2 inhibitors (SGLT2i), or gliflozins, are a group of antidiabetic drugs that have shown improvement in renal and cardiovascular outcomes in patients with kidney disease, with and without diabetes. In this review, we will describe the different proposed mechanisms of acti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fonseca-Correa, Jorge I., Correa-Rotter, Ricardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720766/ https://www.ncbi.nlm.nih.gov/pubmed/34988095 http://dx.doi.org/10.3389/fmed.2021.777861

Ejemplares similares

Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: A mini review
por: Wu, Jinchun, et al.
Publicado: (2022)

Sodium-glucose cotransporter 2 inhibitors’ mechanisms of action in heart failure
por: Grubić Rotkvić, Petra, et al.
Publicado: (2020)

Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure
por: Dutka, Mieczysław, et al.
Publicado: (2020)

Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure
por: Kao, Ting-Wei, et al.
Publicado: (2022)

Potential favorable action of sodium-glucose cotransporter-2 inhibitors on sudden cardiac death: a brief overview
por: Sato, Tatsuya, et al.
Publicado: (2023)

New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
por: Li, Juexing, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease
por: Aftab, Saba, et al.
Publicado: (2020)

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
por: Yang, Fan, et al.
Publicado: (2020)

Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey
por: Cappetta, Donato, et al.
Publicado: (2021)

Early Presentation of a Rare Complication of Sodium-Glucose Cotransporter-2 Inhibitors 10 Days After Initiation: Case Report and Literature Review
por: Elshimy, Ghada, et al.
Publicado: (2019)

Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action
por: Kochanowska, Anna, et al.
Publicado: (2023)

Hypomagnesemia-Induced Hypocalcemia Successfully Treated With Sodium-Glucose Cotransport Inhibitor (SGLT-2i), a Case Report
por: Gandhi, Anand, et al.
Publicado: (2021)

A Review of the Proposed Mechanistic Actions of Sodium Glucose Cotransporter-2 Inhibitors in the Treatment of Heart Failure
por: Nightingale, Brandon
Publicado: (2021)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments
por: Tamargo, Juan
Publicado: (2019)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists
por: Provenzano, Michele, et al.
Publicado: (2021)

Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics
por: Kim, Nam Hoon, et al.
Publicado: (2022)

Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis
por: Koh, Eun Sil, et al.
Publicado: (2023)

The potential of sodium-glucose cotransporter 2 inhibitors for the treatment of systemic right ventricular failure in adults with congenital heart disease
por: Neijenhuis, Ralph M. L., et al.
Publicado: (2023)

Corrigendum to: Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments
por: Tamargo, Juan
Publicado: (2019)

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure
por: Reed, James W
Publicado: (2016)

The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors
por: Ito, Marie, et al.
Publicado: (2018)

Bibliometric and visualized analysis of sodium–Glucose cotransporter 2 inhibitors
por: Sun, He, et al.
Publicado: (2023)

Sodium–glucose cotransporter-2 inhibitors in patients without diabetes
por: Fryml, Elise, et al.
Publicado: (2023)

Exploring the Cardiovascular Benefits of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: Expanding Horizons Beyond Diabetes Management
por: Fatima, Aroob, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter-2 Inhibitors in Nephrology Practice: A Narrative Review
por: Dubrofsky, Lisa, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review
por: Tharmaraja, Thahesh, et al.
Publicado: (2022)

Sodium-glucose cotransporter inhibitors: beyond glycaemic control
por: Vergara, Ander, et al.
Publicado: (2019)

Risk of hypovolemia associated with sodium–glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials
por: Rong, Xi, et al.
Publicado: (2022)

The Possible Mechanisms for Improvement of Liver Function due to Sodium-Glucose Cotransporter-2 Inhibitors
por: Yanai, Hidekatsu, et al.
Publicado: (2019)

Clinical Benefits of Sodium–Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects
por: Kubota, Yoshiaki, et al.
Publicado: (2022)

Scientific evidence of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction: an umbrella review of systematic reviews and meta-analyses
por: Li, Runmin, et al.
Publicado: (2023)

Sodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research
por: Beitelshees, Amber L., et al.
Publicado: (2019)

Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients
por: Uthman, Laween, et al.
Publicado: (2018)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Heart Failure: An Umbrella Review
por: Roy, Raj, et al.
Publicado: (2023)

Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors
por: Yanai, Hidekatsu, et al.
Publicado: (2021)

Increased Hematocrit During Sodium-Glucose Cotransporter-2 Inhibitor Therapy
por: Heyman, Samuel N., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rjv6oigc4305d81po5lp9ljg8d